year 2018 of THB 27 mil., +308% when compared same period of last year regarding to TBSP consolidation and extra finance cost from additional long-term loan for Tender Offer in TBSP. Excluding the extra
, constituting an increase by THB 4.14 million from the same period of 2017, representing a 138.69 percent increase. Such increase was due to settlement of interests on short-term loans in the form of promissory
in financing activities was 5.8 million baht for the three-month period as at March 31, 2019. The company has long-term loans from financial institutions was 5.8 million baht. Date 31 March 2019 31
, net of cash received of short-term loans and repayment of long-term loans. Total shareholders’ equity decreased by 3.5% from the recognition of net loss during the period net with dividend payment. In
report the three-month operating results ending on 31 March 2020, which were reviewed by a certified public accountant. In the consolidated financial statement for the period, the Company booked a net loss
Company”) would like to submit the Management Discussion and Analysis for the second quarter ended June 30, 2020 as follows: Construction and servic revernue For the first six-month period ended 30th June
(“the Company”) would like to submit the Management Discussion and Analysis for the third quarter ended September 30, 2020 as follows: Construction and servic revernue For the first nine-month period
increased by 5.40% year-over-year to Baht 47.95 million in 3Q19 from Baht 45.49 million in 3Q18. (Unit : Million Baht) 30 September 2019 (3 months period) 30 September 2018 (3 months period) Change Revenues
. DOD2019/004 February 20, 2019 Subject: Management’s discussion and analysis of the Company’s operating results for the year 2018 period To: President The Stock Exchange of Thailand DOD Biotech Public
. Profit to equity holders of the company increased by 72.14% year-over-year to Baht 38.44 million in 2Q19 from Baht 22.33 million in 2Q18. (Unit : Million Baht) 30 June 2019 (3 month period) 30 June 2018